Hormone-related Diseases and Prostate Cancer: An English National Record Linkage Study
Overview
Authors
Affiliations
Insulin-like growth factor-I (IGF-I) and testosterone may be related to prostate cancer risk. Acromegaly is associated with clinically high IGF-I concentrations. Klinefelter's syndrome, testicular hypofunction and hypopituitarism are associated with clinically low testosterone concentrations. We aimed to investigate whether diagnosis with these conditions was associated with subsequent prostate cancer diagnosis and mortality. We used linked English national Hospital Episode Statistics and mortality data from 1999 to 2017 to construct and follow-up cohorts of men aged ≥35 years diagnosed with (i) acromegaly (n = 2,495) and (ii) hypogonadal-associated diseases (n = 18,763): Klinefelter's syndrome (n = 1,992), testicular hypofunction (n = 8,086) and hypopituitarism (n = 10,331). We estimated adjusted hazard ratios (HRs) and confidence intervals (CIs) for prostate cancer diagnosis and death using Cox regression in comparison with an unexposed reference cohort of 4.3 million men, who were admitted to hospital for a range of minor surgeries and conditions (n observed cases = 130,000, n prostate cancer deaths = 30,000). For men diagnosed with acromegaly, HR for prostate cancer diagnosis was 1.33 (95% CI 1.09-1.63; p = 0.005; n observed cases = 96), HR for prostate cancer death was 1.44 (95% CI 0.92-2.26; p = 0.11; n deaths = 19). Diagnosis with Klinefelter's syndrome was associated with a lower prostate cancer risk (HR = 0.58, 95% CI 0.37-0.91; p = 0.02; n observed cases = 19) and hypopituitarism was associated with a reduction in prostate cancer death (HR = 0.53, 95% CI 0.35-0.79; p = 0.002; n deaths = 23). These results support the hypothesised roles of IGF-I and testosterone in prostate cancer development and/or progression. These findings are important because they provide insight into prostate cancer aetiology.
Periprostatic Adipose Tissue as a Contributor to Prostate Cancer Pathogenesis: A Narrative Review.
Drewa J, Lazar-Juszczak K, Adamowicz J, Juszczak K Cancers (Basel). 2025; 17(3).
PMID: 39941741 PMC: 11816168. DOI: 10.3390/cancers17030372.
Sarmento-Cabral A, Fuentes-Fayos A, Ordonez F, Leon-Gonzalez A, Martinez-Fuentes A, Gahete M Rev Endocr Metab Disord. 2025; .
PMID: 39910005 DOI: 10.1007/s11154-025-09948-7.
Trecarten S, Liss M, Hamilton-Reeves J, DiGiovanni J Front Immunol. 2025; 15():1448116.
PMID: 39840030 PMC: 11747771. DOI: 10.3389/fimmu.2024.1448116.
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer.
Ravi P, Wang V, Fichorova R, McGregor B, Wei X, Basaria S Endocr Relat Cancer. 2023; 30(11).
PMID: 37671811 PMC: 11304032. DOI: 10.1530/ERC-23-0241.
Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?.
Zha C, Peng Z, Huang K, Tang K, Wang Q, Zhu L Front Oncol. 2023; 13:1196217.
PMID: 37265797 PMC: 10231684. DOI: 10.3389/fonc.2023.1196217.